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Extracellular vesicles as potential tools for regenerative therapy
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ABSTRACT
Small extracellular vesicles released by fibroblasts from young human donors diminish lipid peroxidation 
in senescent cells and in different old mice organs due to their enrichment in Glutathione-S-transferase 
Mu lipid antioxidant activity.
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Aging is characterized by a progressive decline in the physio-
logical function efficiency and by an increased susceptibility to 
disease. This decline is in part mediated by the activation of the 
cellular phenotype named senescence. Cellular senescence is 
characterized by a cell-cycle arrest, and by the senescence- 
associated secretory phenotype, or SASP, that includes the 
secretion of small extracellular vesicles (sEVs), soluble factors, 
and matrix remodeling enzymes.1
We recently showed that sEVs secreted by cells isolated 
from young human healthy individuals (sEV-Y) can ameliorate 
the senescence phenotype in old cells and in old mice by 
reducing lipo-oxidative stress.2
In vitro, different cell types (fibroblasts from old human 
donors, fibroblasts obtained from Hutchison-Gilford progeria 
patients, and young fibroblasts induced to senesce by over-
expression of H-RAS oncogene) were used as old cells to 
determine the ability of sEV-Y to counteract senescence. 
Treatment of old cells with sEV-Y (but not with extracellular 
vesicles from young individuals (EV-Y) larger than 200 nm) 
reduced the levels of senescence markers and revert the pro-
liferation arrest of fibroblasts. One of the most widely used 
biomarkers for senescent cells is the β-Galactosidase staining. 
We could observe that sEV-Y treatment in old mice reduced 
the levels of β-Galactosidase staining in tissue sections of 
different organs like liver, kidney, lung, and brown adipose 
tissue. Similarly, we found a decreased mRNA expression of 
SASP factors in the liver and kidney when old mice were 
treated with sEV-Y.2,3
Previous work from the O´Loghlen lab characterized the 
differential proteomic composition of proliferating versus 
senescent cells sEVs allowed us to identify enzymes of the 
glutathione antioxidant system enriched in sEV-Y.3 In parti-
cular, Glutathione-S-Transferase Mu 2 (encoded by the 
GSTM2 gene) enzyme counteracts lipid oxidation and it 
decreases with age in mice and humans. The oxidation of lipids 
generates highly reactive products such as 4-hydroxynonenal 
(4-HNE) and malondialdehyde (MDA) reactive aldehydes that 
accumulate in senescence, aging, and age-related diseases. We 
observed a decrease in their levels in the liver and serum of 
aged mice after the treatment with sEV-Y enriched in antiox-
idant enzymes.2 Accordingly, Yoshida et al. described that 
extracellular nicotinamide phosphoribosyltransferase enriched 
in EVs enhances Nicotinamide adenine dinucleotide (NAD+) 
biosynthesis once the vesicles are internalized by cells, improv-
ing motor activity and extending lifespan in old mice.4 
Therefore, additional components within sEV-Ys can also con-
tribute to the observed reversion of certain characteristics of 
senescence and aging.
More experimental data are needed to affirm that sEV-Y 
have the ability to rejuvenate young tissues and counteract age- 
related pathologies as happens with cellular reprogramming.5 
We need longer-term experiments, more behavioral and phy-
siological data. In spite of the mounting evidence supporting 
a protective and antioxidant role of sEVs in old individuals, we 
must be cautious before starting to use sEVs in clinical trials to 
counteract aging. EVs are implicated in the development of 
neurodegenerative and cardiovascular diseases, and participate 
in the progress of carcinomas. The sEV composition (ribonu-
cleic acids, proteins, lipids, etc.) depends not only on the age of 
the donor cell, but also on the cell type, physiological condi-
tion, isolation methodology, etc. Cancer, and different stem 
and immune cells secrete sEVs that can influence physiological 
and pathological processes.6-8
However, in our experiments, sEV-Ys are helping aged cells 
and tissues to repair. Therefore, it will be interesting to perform 
long-term experiments, try different administration routes, 
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and test sEV-Y therapeutic capacity in pathological models to 
demonstrate their repairing and rejuvenating abilities.
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